Response to "Letter to the Editor: Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis."
- PMID: 36574849
- DOI: 10.1016/j.jad.2022.12.068
Response to "Letter to the Editor: Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis."
Conflict of interest statement
Conflict of interest Dr. Zarate is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation; as a co-inventor on a patent for the use of (2R,6R)-hydroxynorketamine, (S)-dehydronorketamine, and other stereoisomeric dehydroxylated and hydroxylated metabolites of (R,S)-ketamine metabolites in the treatment of depression and neuropathic pain; and as a co-inventor on a patent application for the use of (2R,6R)-hydroxynorketamine and (2S,6S)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorders. He has assigned his patent rights to the U.S. government but will share a percentage of any royalties the government may receive.
Comment on
-
Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis.J Affect Disord. 2021 Jan 1;278:542-555. doi: 10.1016/j.jad.2020.09.071. Epub 2020 Sep 23. J Affect Disord. 2021. PMID: 33022440 Free PMC article.
-
Letter to the editor about "Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis".J Affect Disord. 2023 Feb 1;322:1. doi: 10.1016/j.jad.2022.10.013. Epub 2022 Oct 18. J Affect Disord. 2023. PMID: 36270446 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources